Comparative real-world outcomes of LifeStream and Viabahn VBX balloon-expandable covered stents for iliac artery occlusive disease

PURPOSE: Balloon-expandable covered stents (CSs) are increasingly used for complex iliac artery occlusive disease, but direct comparative data among CS platforms remain limited. This study compared 1-year restenosis and clinical outcomes between the LifeStream and Viabahn VBX CSs in patients undergoing endovascular treatment (EVT). METHODS: This multicenter retrospective study included 226 patients who underwent EVT for symptomatic iliac artery occlusive disease using either the LifeStream CS (n = 95) or Viabahn VBX CS (n = 131). Outcomes included restenosis, clinically driven target lesion revascularization (CD-TLR), re-occlusion, conversion to bypass surgery, and perioperative complications (POCs). Between-group comparisons were performed using inverse probability of treatment weighting (IPTW) based on propensity scores. RESULTS: One-year follow-up data were available for 163 of 226 patients (72.1%), and 10 restenosis events occurred during follow-up. After IPTW adjustment, the balance of measured covariates was substantially improved. The estimated 1-year freedom from restenosis was 95.8% (95% confidence interval [CI], 93.1-98.6%) in the LifeStream group and 95.8% (95% CI, 93.1-98.6%) in the Viabahn VBX group, with no statistically significant between-group difference (p = 0.99). No significant differences were detected in freedom from CD-TLR (99.2% [95% CI, 98.0-100.0%] vs. 96.7% [95% CI, 94.3-99.2%]; p = 0.13), re-occlusion (100.0% [95% CI, 100.0-100.0%] vs. 98.1% [95% CI, 96.3-99.9%]; p = 0.091), conversion to bypass surgery (100.0% [95% CI, 100.0-100.0%] vs. 98.2% [95% CI, 96.4-100.0%]; p = 0.083), or POCs. CONCLUSION: In this IPTW-adjusted multicenter retrospective study, no statistically significant differences in 1-year restenosis or other clinical outcomes were detected between the LifeStream and Viabahn VBX balloon-expandable CSs. These findings should be considered hypothesis-generating because of the small number of events, incomplete follow-up, and potential residual confounding.

Authors

Institutions

Publication Details

Journal
CVIR Endovascular
Published
2026-11-17
DOI
https://doi.org/10.1186/s42155-026-00802-8
Primary Topic
Peripheral Artery Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative real-world outcomes of LifeStream and Viabahn VBX balloon-expandable covered stents for iliac artery occlusive disease

Kenji Ogata, Yoshimitsu Soga, Yusuke Tomoi, Kenji Andò et al.
CVIR Endovascular
Peripheral Artery Disease Management
article

Comparative real-world outcomes of LifeStream and Viabahn VBX balloon-expandable covered stents for iliac artery occlusive disease

Kenji Ogata, Yoshimitsu Soga, Yusuke Tomoi, Kenji Andò, Mitsuyoshi Takahara, Tatsuro Takei
article en

Abstract

PURPOSE: Balloon-expandable covered stents (CSs) are increasingly used for complex iliac artery occlusive disease, but direct comparative data among CS platforms remain limited. This study compared 1-year restenosis and clinical outcomes between the LifeStream and Viabahn VBX CSs in patients undergoing endovascular treatment (EVT). METHODS: This multicenter retrospective study included 226 patients who underwent EVT for symptomatic iliac artery occlusive disease using either the LifeStream CS (n = 95) or Viabahn VBX CS (n = 131). Outcomes included restenosis, clinically driven target lesion revascularization (CD-TLR), re-occlusion, conversion to bypass surgery, and perioperative complications (POCs). Between-group comparisons were performed using inverse probability of treatment weighting (IPTW) based on propensity scores. RESULTS: One-year follow-up data were available for 163 of 226 patients (72.1%), and 10 restenosis events occurred during follow-up. After IPTW adjustment, the balance of measured covariates was substantially improved. The estimated 1-year freedom from restenosis was 95.8% (95% confidence interval [CI], 93.1-98.6%) in the LifeStream group and 95.8% (95% CI, 93.1-98.6%) in the Viabahn VBX group, with no statistically significant between-group difference (p = 0.99). No significant differences were detected in freedom from CD-TLR (99.2% [95% CI, 98.0-100.0%] vs. 96.7% [95% CI, 94.3-99.2%]; p = 0.13), re-occlusion (100.0% [95% CI, 100.0-100.0%] vs. 98.1% [95% CI, 96.3-99.9%]; p = 0.091), conversion to bypass surgery (100.0% [95% CI, 100.0-100.0%] vs. 98.2% [95% CI, 96.4-100.0%]; p = 0.083), or POCs. CONCLUSION: In this IPTW-adjusted multicenter retrospective study, no statistically significant differences in 1-year restenosis or other clinical outcomes were detected between the LifeStream and Viabahn VBX balloon-expandable CSs. These findings should be considered hypothesis-generating because of the small number of events, incomplete follow-up, and potential residual confounding.

CVIR EndovascularVol. 9(1)
Kokura Memorial Hospital (JP), Miyazaki Medical Association Hospital (JP), The University of Osaka (JP)
Good health and well-being
Peripheral Artery Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon